featured
2022 Top Story in Advanced Melanoma: Adjuvant Anti–PD-1 for Stage IIB/C Melanoma
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Luke JJ, Rutkowski P, Queirolo P, et al: Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022. 399(10336):1718-1729.
- Long G. Adjuvant therapy with nivolumab versus placebo in patients with stage IIB/C melanoma (CheckMate 76K). Paper presented at: 19th International Congress of the Society for Melanoma Research. October 19, 2022; Edinburgh, Scotland.
- van Akkooi AC. Design and Testing of a Custom Melanoma NGS Panel for Analysis of ctDNA [abstract of Diefenbach RJ, Lee JH, Menzies AM, et al. Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. Cancers (Basel). 2020;12(8):2228]. PracticeUpdate Advanced Melanoma. 2020 Sep 10. Accessed October 27, 2022.
- van Akkooi. Prognostic Gene-Expression Profiling in Cutaneous Melanoma [abstract of Grossman D, Okwundu N, Bartlett EK. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol. 2020;156(9):1004-1011]. PracticeUpdate Advanced Melanoma. 2020 Aug 19. Accessed October 27, 2022.
Disclosure statements are available on the authors' profiles: